Glycolic acid and/or D-lactic acid for the treatment of neurodegenerative diseases

Patent metadata

Field	Value
Publication number	US-10434077-B2
Application number	US-201515532930-A
Country	US
Kind code	B2
Filing date	Mar 31, 2015
Priority date	Mar 31, 2014
Publication date	Oct 8, 2019
Grant date	Oct 8, 2019

Abstract

A method of treatment of a neurodegenerative disease which is associated with a decline in mitochondrial activity, includes administering to a person in need of such treatment at least one of Glycolic acid or a pharmaceutically acceptable salt or ester thereof, and D-lactic acid or a pharmaceutically acceptable salt or ester thereof.

First claim

The invention claimed is:

1. A method of treatment of a neurodegenerative disease which is associated with a decline in mitochondrial activity, said method comprising administering to a person in need of such treatment for a neurodegenerative disease with decline in mitochondrial activity, a therapeutically effective amount of glycolic acid or a pharmaceutically acceptable salt thereof, and optionally D-lactic acid or a pharmaceutically acceptable salt or ester thereof.

2. The method of claim 1 , wherein said disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, and other neurodegenerative diseases.

3. The method of claim 2 , wherein the disease is Parkinson's disease.

4. The method of claim 1 , wherein the glycolic acid or a pharmaceutically acceptable salt thereof, and the D-lactic acid or a pharmaceutically acceptable salt or ester thereof are comprised in a formulation, said formulation containing
(i) glycolic acid or a pharmaceutically acceptable salt thereof, in an amount of at least 0.005% (w/w), and
(ii) D-lactic acid or a pharmaceutically acceptable salt or ester thereof in an amount of at least 1.0% (w/w).

5. The method of claim 1 , further comprising administering pyruvate to said person.

6. The method of claim 1 , further comprising administering one or more antioxidants to said person.

7. The method of claim 6 , where the antioxidants comprise coenzyme Q10.

8. The method of claim 1 , further comprising administering one or more vitamins to said person.

9. The method of claim 8 , wherein said one or more vitamins are selected from the group consisting of vitamin E, C, B2 and B9.

10. The method of claim 1 , further comprising administering one or more compounds selected from the group consisting of L-arginine, L-camitine and L-creatine to said person.

11. The method of claim 1 , wherein the glycolic acid or the pharmaceutically acceptable salt thereof, or the D-lactic acid or the pharmaceutically acceptable salt or ester thereof is formulated as a medical food or medical food supplement.

12. The method of claim 11 , wherein the medical food or medical food supplement is a milk-based medical food or milk-based medical food supplement.

Assignees

• Max Planck Gesellschaft

Inventors

• Kurzchalia Teymuras
• Hyman Anthony A
• Toyoda Yusuke
• Pan-Montojo Francisco
• Erkut Cihan

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/122

  having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A23L33/10

  using additives (addition of substantially indigestible substances A23L33/21) · CPC title